John W. Ripple

Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA.

Ensemble Therapeutics Corp. develops novel classes of therapeutics and bioassays for research and diagnostics. The firm focuses on the discovery and development of breakthrough small molecule therapies for patients with cancer and other serious diseases. The company was founded by Douglas G. Cole, Noubar B. Afeyan and David R. Liu in 2004 and is headquartered in Cambridge, MA.

Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA.

Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA.

Virdante Pharmaceuticals, Inc. develops and commercializes drugs for auto-immune and inflammatory disorders. The company's products incorporate a proprietary 'sialic switch' technology to improve the anti-inflammatory properties of antibodies. It was founded in 2008 and is headquartered in Cambridge, MA.

Permeon Biologics, Inc. develops intracellular biotherapeutics platform to enhance drug delivery. Its intraphilin technology platform leverages research on remodeling the surfaces of proteins to permit cell penetration without losing their structure or activity; and enables functional proteins to replace or restore defective pathways inside cells that cause disease. The company was founded by Douglas G. Cole, David R. Liu, John W. Ripple, and Noubar B. Afeyan in 2008 and is headquartered in Cambridge, MA.

Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA.

Praesidia Biotherapeutics, Inc. is a company that specializes in developing drugs using their proprietary Tunable Linker Technology called LESS (Linker Enzyme Substrate System). The company is based in Arlington, MA. This technology helps to maximize the therapeutic potential of drugs. The company was founded by Sohang Chatterjee, Pradip K. Majumder, and Santosh Kesari, with Sohang Chatterjee serving as the CEO since incorporation.